サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1402453

欧州の臨床試験市場の2028年までの予測-地域別分析-試験設計、フェーズ、適応症別

Europe Clinical Trials Market Forecast to 2028 - Regional Analysis - by Study Design, Phase, and Indication
出版日: | 発行: The Insight Partners | ページ情報: 英文 148 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
欧州の臨床試験市場の2028年までの予測-地域別分析-試験設計、フェーズ、適応症別
出版日: 2023年10月26日
発行: The Insight Partners
ページ情報: 英文 148 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の臨床試験市場は、2022年の157億3,935万米ドルから2028年には216億4,387万米ドルに成長すると予測されています。2022年から2028年までのCAGRは5.5%と推定されます。

臨床試験の採用とアウトソーシングの増加が欧州の臨床試験市場を後押し

臨床試験は、新薬、食事療法、医療機器などの新しい治療法や予防法が安全で効果的かどうかを判断するのに役立ちます。臨床試験は主に医薬品開発中に実施されます。欧州医薬品庁によると、欧州連合（EU）では年間約4,000件の臨床試験が認可されており、そのうち約60％が製薬業界に関連したものです。慢性疾患の増加により、さまざまな有効な治療法を開発するための臨床試験が増加していることが、臨床試験市場の成長を後押ししています。

さらに、臨床試験はますます複雑な手順になってきており、そのため、研究ベースの組織で発生する業務の適切な実行と監督が重要になってきています。不適切な実施によるエラーを回避するため、研究開発型組織は製品開発のために臨床試験をアウトソーシングしています。臨床研究機関（CRO）は、質の高い施設と深い専門知識を用いて提供されるサービスを通じて、臨床試験を成功裏に実施するための支援を行っています。CROは、効率的で費用対効果の高い業務を通じて臨床試験依頼者に利益をもたらし、臨床試験業界の屋台骨として機能し始めています。このように、費用対効果の高いソリューションの開発と、医薬品市場開拓プロセスにおけるCROのミスの減少が、臨床試験市場の成長を促進しています。

欧州の臨床試験市場概要

欧州の臨床試験市場は、英国、ドイツ、フランス、イタリア、スペイン、その他の欧州に区分されます。新薬開発のための臨床試験活動の増加や、企業による革新的な製品の上市により、予測期間中、欧州の市場成長が促進される可能性が高いです。

がん、心血管疾患、神経系疾患、感染症は、ドイツの臨床試験で最も頻繁に研究されている疾患です。臨床研究は、交通、通信、エネルギー、公共サービスのインフラが確立しているドイツの恩恵を受けています。学術的臨床研究を促進するため、連邦教育研究省の新しい資金援助プログラムの一環として、臨床試験の調整センターが設立されました。ドイツにおける臨床試験は、調査対象製品に応じて連邦医薬品・医療機器研究所またはパウル・エルリッヒ研究所によって承認されます。そのため、ドイツの臨床試験承認プロセスは標準化されており、信頼性、透明性が高く、比較的短い試験開始スケジュールで承認されます。さらに、ドイツのトップCROは、いくつかの臨床試験サービスを提供しています。ソフプロメッドは、ドイツと他のEU加盟国での臨床試験を管理しています。同社は製薬会社やバイオテクノロジー企業に対し、あらゆるCROサービスを提供しています。同様に、ドイツのマンハイムに本社を置くCONET GmbHは、EU指令に基づく小児臨床試験や医療機器試験を含め、小規模なパイロット試験から大規模な多施設国際臨床試験まで、あらゆるフェーズ（1～4）の臨床試験管理サービスを提供しています。

欧州の臨床試験市場の収益と2028年までの予測（金額）

欧州の臨床試験市場のセグメンテーション

欧州の臨床試験市場は、フェーズ、試験設計、適応症、国別に区分されます。

フェーズに基づき、欧州の臨床試験市場はフェーズi、フェーズII、フェーズIII、フェーズIVに区分されます。第III相セグメントは2022年に欧州の臨床試験市場で最大のシェアを記録しました。

試験設計に基づき、欧州の臨床試験市場は介入、観察、拡大アクセスに区分されます。インターベンショナルセグメントは2022年に欧州の臨床試験市場で最大のシェアを占めました。

適応症に基づき、欧州の臨床試験市場は自己免疫/炎症、疼痛管理、腫瘍、中枢神経系疾患、糖尿病、肥満、心血管、その他に区分されます。2022年の欧州の臨床試験市場シェアは、がん領域が最大でした。

国別に見ると、欧州の臨床試験市場は英国、ドイツ、フランス、イタリア、スペイン、その他の欧州に分類されます。ドイツは2022年の欧州の臨床試験市場を独占しました。

Charles River Laboratories International Inc、ICON Plc、IQVIA Holdings Inc、IXICO Plc、Laboratory Corp of America Holdings、Parexel International Corp、SGS SA、Syneos Health Inc、Thermo Fisher Scientific Inc、WuXi AppTec Co Ltd.は、欧州の臨床試験市場で事業を展開する大手企業の一部です。

目次

第1章 イントロダクション

第2章 キーポイント

第3章 調査手法

  • カバー範囲
  • 2次調査
  • 1次調査

第4章 欧州の臨床試験市場-市場情勢

  • イントロダクション
  • PEST分析
    • 欧州PEST分析
  • 専門家の見解

第5章 欧州の臨床試験市場-主要市場力学

  • 市場の促進要因
    • 臨床試験の採用とアウトソーシングの増加
    • 製薬業界の繁栄と研究開発活動の活発化
  • 市場抑制要因
    • 高価で時間のかかるプロセス
  • 市場機会
    • 分散型臨床試験とハイブリッド臨床試験の採用
  • 今後の動向
    • AI主導臨床試験
  • 影響分析

第6章 臨床試験市場-欧州分析

  • 欧州臨床試験市場の収益予測と分析

第7章 欧州の臨床試験市場：2028年までの収益と予測：試験設計別

  • イントロダクション
  • 欧州の臨床試験市場の研究設計別収益シェア（2022年、2028年）
  • 介入試験
  • 観察研究
  • 拡大アクセス

第8章 欧州の臨床試験市場：2028年までの収益と予測：フェーズ別

  • イントロダクション
  • 欧州の臨床試験市場、フェーズ別、2022年と2028年（%）
  • フェーズIII
  • フェーズII
  • フェーズIV
  • フェーズI

第9章 欧州の臨床試験市場：2028年までの収益と予測：適応症

  • イントロダクション
  • 欧州の臨床試験市場の適応症別売上高シェア（2022年、2028年）
  • 自己免疫/炎症
  • 疼痛管理
  • 腫瘍学
  • 中枢神経系疾患
  • 糖尿病
  • 肥満症
  • 心血管
  • その他

第10章 欧州の臨床試験市場：2028年までの収益と予測：国別分析

  • 欧州
  • 概要

    第11章 業界情勢

    • イントロダクション
    • 市場参入企業の成長戦略（%）
    • 有機的展開
    • 概要
    • 無機的展開
    • 概要

    第12章 企業プロファイル

    • IQVIA Holdings Inc
    • Parexel International Corp
    • IXICO Plc
    • Charles River Laboratories International Inc
    • ICON Plc
    • WuXi AppTec Co Ltd
    • SGS SA
    • Syneos Health Inc
    • Thermo Fisher Scientific Inc
    • Laboratory Corp of America Holdings

    第13章 付録

    • 図表

    List Of Tables

    • Table 1. Germany: Clinical Trials Market, by Phase - Revenue and Forecast to 2028 (US$ Million)
    • Table 2. Germany: Clinical Trials Market, by Study Design - Revenue and Forecast to 2028 (US$ Million)
    • Table 3. Germany: Clinical Trials Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
    • Table 4. UK Clinical Trials Market, by Phase - Revenue and Forecast to 2028 (US$ Million)
    • Table 5. UK Clinical Trials Market, by Study Design - Revenue and Forecast to 2028 (US$ Million)
    • Table 6. UK Clinical Trials Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
    • Table 7. France: Clinical Trials Market, by Phase - Revenue and Forecast to 2028 (US$ Million)
    • Table 8. France: Clinical Trials Market, by Study Design - Revenue and Forecast to 2028 (US$ Million)
    • Table 9. France: Clinical Trials Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
    • Table 10. Italy: Clinical Trials Market, by Phase - Revenue and Forecast to 2028 (US$ Million)
    • Table 11. Italy: Clinical Trials Market, by Study Design - Revenue and Forecast to 2028 (US$ Million)
    • Table 12. Italy: Clinical Trials Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
    • Table 13. Spain: Clinical Trials Market, by Phase - Revenue and Forecast to 2028 (US$ Million)
    • Table 14. Spain: Clinical Trials Market, by Study Design - Revenue and Forecast to 2028 (US$ Million)
    • Table 15. Spain: Clinical Trials Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
    • Table 16. Rest of Europe: Clinical Trials Market, by Phase - Revenue and Forecast to 2028 (US$ Million)
    • Table 17. Rest of Europe: Clinical Trials Market, by Study Design - Revenue and Forecast to 2028 (US$ Million)
    • Table 18. Rest of Europe: Clinical Trials Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
    • Table 19. Organic Developments Done by Companies
    • Table 20. Inorganic Developments Done by Companies
    • Table 21. Glossary of Terms

    List Of Figures

    • Figure 1. Europe Clinical Trials Market Segmentation
    • Figure 2. Europe Clinical Trials Market, By Region
    • Figure 3. Europe Clinical Trials Market Overview
    • Figure 4. Phase III Segment Held Largest Share of Phase Segment in Europe Clinical Trials Market
    • Figure 5. The UK is Expected to Show Remarkable Growth During the Forecast Period
    • Figure 6. Europe: PEST Analysis
    • Figure 7. Europe Experts Opinion
    • Figure 8. Impact Analysis
    • Figure 9. Europe Clinical Trials Market- Revenue Forecast and Analysis - 2020- 2028
    • Figure 10. Europe Clinical Trials Market Revenue Share, by Study Design (2022 and 2028)
    • Figure 11. Interventional: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 12. Observational: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 13. Expanded Access: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 14. Europe Clinical Trials Market, by Phase 2022 and 2028 (%)
    • Figure 15. Phase III: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 16. Phase II: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 17. Phase IV: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 18. Phase I: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 19. Europe Clinical Trials Market Revenue Share, by Indication (2022 and 2028)
    • Figure 20. Autoimmune/Inflammation: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 21. Pain Management: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 22. Oncology: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 23. CNS Condition: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 24. Diabetes: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 25. Obesity: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 26. Cardiovascular: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 27. Other: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 28. Europe: Clinical Trials Market, by Key Country - Revenue (2022) (US$ Million)
    • Figure 29. Europe: Clinical Trials Market, by Country, 2022 & 2028 (%)
    • Figure 30. Germany: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 31. UK: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 32. France: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 33. Italy: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 34. Spain: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 35. Rest of Europe: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • Figure 36. Growth Strategies Done by the Companies in the Market, (%)
    目次
    Product Code: BMIRE00028989

    The Europe clinical trials market is expected to grow from US$ 15,739.35 million in 2022 to US$ 21,643.87 million by 2028. It is estimated to grow at a CAGR of 5.5% from 2022 to 2028.

    Increasing Adoption and Outsourcing of Clinical Trials Fuels Europe clinical trials market.

    Clinical trials help determine if a new form of treatment or prevention, such as a new drug, diet, or medical device, is safe and effective. The trials are mainly carried out during drug development. According to European Medicine Agency, in the European Union (EU), ~4,000 clinical trials are authorized annually, of which about 60% of clinical trials are associated with the pharmaceutical industry. An increasing number of clinical trials for developing different effective treatments due to the rising prevalence of chronic diseases is fueling the growth of the clinical trials market.

    Further, clinical trials are increasingly becoming complex procedures, owing to which proper execution and overseeing of the operation occurring in research-based organizations has become crucial. To avoid errors due to improper execution, research-based organizations are outsourcing clinical trials to develop their products. Clinical research organizations (CROs) assist in successfully implementing clinical trials through the services offered using high-quality facilities and deep subject matter expertise. CROs have begun acting as a backbone of the clinical trial industry through their efficient and cost-effective operations benefitting trial sponsors. Thus, the development of cost-effective solutions and decreasing errors in CROs during the drug development process are driving the clinical trials market growth.

    Europe Clinical Trials Market Overview

    The Europe clinical trials market has been segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The rising number of clinical trial activities for new drug development and innovative product launches by the companies will likely enhance the market growth in Europe during the forecast period.

    Cancer, cardiovascular illness, nervous system disorders, and infectious diseases are the most frequently studied conditions in clinical trials in Germany. Clinical research benefits from Germany's well-established transport, communication, energy, and public services infrastructure, Moreover, there is a large patient pool and a high demand for quality healthcare in the country. Coordinating centers for clinical trials were established as part of a new funding program under the Federal Ministry of Education and Research to foster academic clinical research. Clinical trials in Germany are approved by the Federal Institute for Drugs and Medical Devices or the Paul-Ehrlich Institute, depending on the product to be investigated. Therefore, Germany's clinical trial approval processes are standardized, reliable, transparent, and approved for relatively short study start-up timelines. Further, top CROs in Germany provide several clinical trial services. Sofpromed manages clinical trials in Germany and other EU member states. It offers a full range of CRO services for pharmaceutical and biotechnology companies. Similarly, CONET GmbH, headquartered in Mannheim, Germany, offers clinical trial management services from small pilot studies to large multicenter international clinical trials for all phases (1-4), including pediatric clinical trials and medical device trials as per EU Directives.

    Europe clinical trials market Revenue and Forecast to 2028 (US$ Million)

    Europe Clinical Trials Market Segmentation

    The Europe clinical trials market is segmented into phase, study design, indication, and country.

    Based on phase, the Europe clinical trials market is segmented into phase I, phase II, phase III, and phase IV. The phase III segment registered the largest Europe clinical trials market share in 2022.

    Based on study design, the Europe clinical trials market is segmented into interventional, observational, and expanded access. The interventional segment held the largest Europe clinical trials market share in 2022.

    Based on indication, the Europe clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, CNS condition, diabetes, obesity, cardiovascular, and others. The oncology segment held the largest Europe clinical trials market share in 2022.

    Based on country, the Europe clinical trials market has been categorized into the UK, Germany, France, Italy, Spain, and Rest of Europe. Germany dominated the Europe clinical trials market in 2022.

    Charles River Laboratories International Inc, ICON Plc, IQVIA Holdings Inc, IXICO Plc, Laboratory Corp of America Holdings, Parexel International Corp, SGS SA, Syneos Health Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd. are some of the leading companies operating in the Europe clinical trials market.

    Reasons to Buy:

    • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe clinical trials market.
    • Highlights key business priorities in order to assist companies to realign their business strategies
    • The key findings and recommendations highlight crucial progressive industry trends in the Europe clinical trials market, thereby allowing players across the value chain to develop effective long-term strategies
    • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
    • Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the clinical trials market, as well as those hindering it
    • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

    Table Of Contents

    1. Introduction

    • 1.1 Scope of the Study
    • 1.2 The Insight Partners Research Report Guidance
    • 1.3 Market Segmentation
      • 1.3.1 Europe Clinical Trials Market - By Phase
      • 1.3.2 Europe Clinical Trials Market - By Study Design
      • 1.3.3 Europe Clinical Trials Market - By Indication
      • 1.3.4 Europe Clinical Trials Market - By Country

    2. Key Takeaways

    3. Research Methodology

    • 3.1 Coverage
    • 3.2 Secondary Research
    • 3.3 Primary Research

    4. Europe Clinical Trials Market - Market Landscape

    • 4.1 Overview
    • 4.2 PEST Analysis
      • 4.2.1 Europe PEST Analysis
    • 4.3 Experts Opinion

    5. Europe Clinical Trials Market - Key Market Dynamics

    • 5.1 Market Drivers
      • 5.1.1 Increasing Adoption and Outsourcing of Clinical Trials
      • 5.1.2 Flourishing Pharmaceutical Industry and Increasing R&D Activities in Pharmaceutical Industry
    • 5.2 Market Restraints
      • 5.2.1 Expensive and Time-Consuming Process
    • 5.3 Market Opportunities
      • 5.3.1 Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials
    • 5.4 Future Trends
      • 5.4.1 AI-Driven Clinical Trials
    • 5.5 Impact Analysis

    6. Clinical Trials Market - Europe Analysis

    • 6.1 Europe Clinical Trials Market Revenue Forecast and Analysis

    7. Europe Clinical Trials Market Revenue and Forecast To 2028 - by Study Design

    • 7.1 Overview
    • 7.2 Europe Clinical Trials Market Revenue Share, by Study Design (2022 and 2028)
    • 7.3 Interventional
      • 7.3.1 Overview
      • 7.3.2 Interventional: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4 Observational
      • 7.4.1 Overview
      • 7.4.2 Observational: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.5 Expanded Access
      • 7.5.1 Overview
      • 7.5.2 Expanded Access: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)

    8. Europe Clinical Trials Market - By Phase

    • 8.1 Overview
    • 8.2 Europe Clinical Trials Market, by Phase, 2022 and 2028 (%)
    • 8.3 Phase III
      • 8.3.1 Overview
      • 8.3.2 Phase III: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.4 Phase II
      • 8.4.1 Overview
      • 8.4.2 Phase II: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.5 Phase IV
      • 8.5.1 Overview
      • 8.5.2 Phase IV: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.6 Phase I
      • 8.6.1 Overview
      • 8.6.2 Phase I: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)

    9. Europe Clinical Trials Market Revenue and Forecast To 2028 - Indication

    • 9.1 Overview
    • 9.2 Europe Clinical Trials Market Revenue Share, by Indication (2022 and 2028)
    • 9.3 Autoimmune/Inflammation
      • 9.3.1 Overview
      • 9.3.2 Autoimmune/Inflammation: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • 9.4 Pain Management
      • 9.4.1 Overview
      • 9.4.2 Pain Management: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • 9.5 Oncology
      • 9.5.1 Overview
      • 9.5.2 Oncology: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • 9.6 CNS Condition
      • 9.6.1 Overview
      • 9.6.2 CNS Condition: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • 9.7 Diabetes
      • 9.7.1 Overview
      • 9.7.2 Diabetes: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • 9.8 Obesity
      • 9.8.1 Overview
      • 9.8.2 Obesity: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • 9.9 Cardiovascular
      • 9.9.1 Overview
      • 9.9.2 Cardiovascular: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
    • 9.10 Other
      • 9.10.1 Overview
      • 9.10.2 Other: Europe Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)

    10. Europe Clinical Trials Market - Revenue and Forecast to 2028 - Country Analysis

    • 10.1 Europe: Clinical Trials Market
      • 10.1.1 Overview
      • 10.1.2 Europe: Clinical Trials Market, by Country, 2022 & 2028 (%)
        • 10.1.2.1 Germany: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
          • 10.1.2.1.1 Overview
          • 10.1.2.1.2 Germany: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
          • 10.1.2.1.3 Germany: Clinical Trials Market, by Phase, 2020-2028 (US$ Million)
          • 10.1.2.1.4 Germany: Clinical Trials Market, by Study Design, 2020-2028 (US$ Million)
          • 10.1.2.1.5 Germany: Clinical Trials Market, by Indication, 2020-2028 (US$ Million)
        • 10.1.2.2 UK: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
          • 10.1.2.2.1 Overview
          • 10.1.2.2.2 UK: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
          • 10.1.2.2.3 UK: Clinical Trials Market, by Phase, 2020-2028 (US$ Million)
          • 10.1.2.2.4 UK: Clinical Trials Market, by Study Design, 2020-2028 (US$ Million)
          • 10.1.2.2.5 UK: Clinical Trials Market, by Indication, 2020-2028 (US$ Million)
        • 10.1.2.3 France: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
          • 10.1.2.3.1 Overview
          • 10.1.2.3.2 France: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
          • 10.1.2.3.3 France: Clinical Trials Market, by Phase, 2020-2028 (US$ Million)
          • 10.1.2.3.4 France: Clinical Trials Market, by Study Design, 2020-2028 (US$ Million)
          • 10.1.2.3.5 France: Clinical Trials Market, by Indication, 2020-2028 (US$ Million)
        • 10.1.2.4 Italy: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
          • 10.1.2.4.1 Overview
          • 10.1.2.4.2 Italy: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
          • 10.1.2.4.3 Italy: Clinical Trials Market, by Phase, 2020-2028 (US$ Million)
          • 10.1.2.4.4 Italy: Clinical Trials Market, by Study Design, 2020-2028 (US$ Million)
          • 10.1.2.4.5 Italy: Clinical Trials Market, by Indication, 2020-2028 (US$ Million)
        • 10.1.2.5 Spain: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
          • 10.1.2.5.1 Overview
          • 10.1.2.5.2 Spain: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
          • 10.1.2.5.3 Spain: Clinical Trials Market, by Phase, 2020-2028 (US$ Million)
          • 10.1.2.5.4 Spain: Clinical Trials Market, by Study Design, 2020-2028 (US$ Million)
          • 10.1.2.5.5 Spain: Clinical Trials Market, by Indication, 2020-2028 (US$ Million)
        • 10.1.2.6 Rest of Europe: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
          • 10.1.2.6.1 Overview
          • 10.1.2.6.2 Rest of Europe: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
          • 10.1.2.6.3 Rest of Europe: Clinical Trials Market, by Phase, 2020-2028 (US$ Million)
          • 10.1.2.6.4 Rest of Europe: Clinical Trials Market, by Study Design, 2020-2028 (US$ Million)
          • 10.1.2.6.5 Rest of Europe: Clinical Trials Market, by Indication, 2020-2028 (US$ Million)

    11. Industry Landscape

    • 11.1 Overview
    • 11.2 Growth Strategies Done by the Companies in the Market, (%)
    • 11.3 Organic Developments
      • 11.3.1 Overview
    • 11.4 Inorganic Developments
      • 11.4.1 Overview

    12. Company Profiles

    • 12.1 IQVIA Holdings Inc
      • 12.1.1 Key Facts
      • 12.1.2 Business Description
      • 12.1.3 Products and Services
      • 12.1.4 Financial Overview
      • 12.1.5 SWOT Analysis
      • 12.1.6 Key Developments
    • 12.2 Parexel International Corp
      • 12.2.1 Key Facts
      • 12.2.2 Business Description
      • 12.2.3 Products and Services
      • 12.2.4 Financial Overview
      • 12.2.5 SWOT Analysis
      • 12.2.6 Key Developments
    • 12.3 IXICO Plc
      • 12.3.1 Key Facts
      • 12.3.2 Business Description
      • 12.3.3 Products and Services
      • 12.3.4 Financial Overview
      • 12.3.5 SWOT Analysis
      • 12.3.6 Key Developments
    • 12.4 Charles River Laboratories International Inc
      • 12.4.1 Key Facts
      • 12.4.2 Business Description
      • 12.4.3 Products and Services
      • 12.4.4 Financial Overview
      • 12.4.5 SWOT Analysis
      • 12.4.6 Key Developments
    • 12.5 ICON Plc
      • 12.5.1 Key Facts
      • 12.5.2 Business Description
      • 12.5.3 Products and Services
      • 12.5.4 Financial Overview
      • 12.5.5 SWOT Analysis
      • 12.5.6 Key Developments
    • 12.6 WuXi AppTec Co Ltd
      • 12.6.1 Key Facts
      • 12.6.2 Business Description
      • 12.6.3 Products and Services
      • 12.6.4 Financial Overview
      • 12.6.5 SWOT Analysis
      • 12.6.6 Key Developments
    • 12.7 SGS SA
      • 12.7.1 Key Facts
      • 12.7.2 Business Description
      • 12.7.3 Products and Services
      • 12.7.4 Financial Overview
      • 12.7.5 SWOT Analysis
      • 12.7.6 Key Developments
    • 12.8 Syneos Health Inc
      • 12.8.1 Key Facts
      • 12.8.2 Business Description
      • 12.8.3 Products and Services
      • 12.8.4 Financial Overview
      • 12.8.5 SWOT Analysis
      • 12.8.6 Key Developments
    • 12.9 Thermo Fisher Scientific Inc
      • 12.9.1 Key Facts
      • 12.9.2 Business Description
      • 12.9.3 Products and Services
      • 12.9.4 Financial Overview
      • 12.9.5 SWOT Analysis
      • 12.9.6 Key Developments
    • 12.10 Laboratory Corp of America Holdings
      • 12.10.1 Key Facts
      • 12.10.2 Business Description
      • 12.10.3 Products and Services
      • 12.10.4 Financial Overview
      • 12.10.5 SWOT Analysis
      • 12.10.6 Key Developments

    13. Appendix

    • 13.1 About The Insight Partners
    • 13.2 Glossary of Terms